Cytokinetics Inc’s filing revealed that its EVP, Chief Commercial Officer Callos Andrew unloaded Company’s shares for reported $0.9 million on Jan 05 ’26. In the deal valued at $60.28 per share,15,000 shares were sold. As a result of this transaction, Callos Andrew now holds 50,440 shares worth roughly $3.09 million.
Then, Callos Andrew sold 1,798 shares, generating $112,585 in total proceeds. Upon selling the shares at $62.62, the EVP, Chief Commercial Officer now owns 50,440 shares.
Before that, ANDREW CALLOS bought 59,570 shares. Cytokinetics Inc shares valued at $3,785,078 were divested by the Officer at a price of $63.54 per share.
Goldman upgraded its Cytokinetics Inc [CYTK] rating to a Buy from a a Neutral in a research note published recently. Barclays began covering CYTK with “an Overweight” recommendation on April 24, 2025. Citigroup started covering the stock on February 07, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Monday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -0.76% to $61.26. Over the last five days, the stock has lost -2.93%. Cytokinetics Inc shares have risen nearly 30.23% since the year began. Nevertheless, the stocks have fallen -3.59% over the past one year. While a 52-week high of $70.98 was reached on 01/02/26, a 52-week low of $29.31 was recorded on 01/05/26.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 59.52, which if violated will result in even more drops to 57.78. On the upside, there is a resistance level at 62.33. A further resistance level may holdings at 63.40.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-12-15, dropping by -1.04 million shares to a total of 13.34 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 14.38 million shares. There was a decline of -7.8%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 22, 2025 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $80 price target.
